According to the FDA, aducanumab (Aduhelm), the recently approved anti-Alzheimer 
drug, reduces the level of cerebral amyloid plaques-a hallmark finding in 
patients with Alzheimer's disease-and this will result in a reduction in 
clinical decline. The authors of this article are not convinced that amyloid 
deposits are a hallmark of Alzheimer's disease and are of the opinion that the 
apparent reduction in amyloid accumulation following aducanumab treatment is 
likely instead a result of continued and advanced cerebral cell death and, thus, 
not a sign of improvement but of an even more advanced disease.